CTOs on the Move

Carisma Therapeutics

www.carmatherapeutics.com

 
Carisma Therapeutics is pioneering the development of CAR macrophages, a disruptive approach to immunotherapy. Our technology leverages advances in macrophage biology, chimeric antigen receptor engineering and adoptive cellular therapy for the treatment of human disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Carisma Therapeutics raised $53M on 06/27/2018

Similar Companies

Roivant

Roivant Sciences is a global healthcare company focused on realizing the full value of promising biomedical research to improve the lives of patients and their families. Roivant`s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the broader healthcare system. Roivant is a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas. We deliver R&D solutions to our partners in the biopharmaceutical industry, helping them unlock value from their pipelines by completing the clinical development of promising drug candidates. Our pipeline spans multiple therapeutic areas through partnerships with academic institutions and pharmaceutical companies, including Takeda, Merck, GlaxoSmithKline, Vertex, Eisai, Arena Pharmaceuticals, Portola Pharmaceutcals, Duke University, and Cincinnati Children`s Hospital Medical Center.

Southern Research Institute

Southern Research Institute is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vitaflo USA

Vitaflo USA is a Alexandria, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Applied Genetic Technologies Corporation

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC`s lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC`s product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products